Kanamycin Incorporation In Lipid Vesicles Prepared By Ethanol Injection Designed For Tuberculosis Treatment.

dc.creatorJusto, Oselys Rodriguez
dc.creatorMoraes, Angela Maria
dc.date2005-Jan
dc.date2015-11-27T13:02:04Z
dc.date2015-11-27T13:02:04Z
dc.date.accessioned2018-03-29T01:00:47Z
dc.date.available2018-03-29T01:00:47Z
dc.identifierThe Journal Of Pharmacy And Pharmacology. v. 57, n. 1, p. 23-30, 2005-Jan.
dc.identifier0022-3573
dc.identifier10.1211/0022357055092
dc.identifierhttp://www.ncbi.nlm.nih.gov/pubmed/15638989
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/196249
dc.identifier15638989
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1296482
dc.descriptionThe primary goal of this study was the production of liposomes encapsulating kanamycin for drug administration by inhalation. The selected drug is indicated for multiresistant tuberculosis, and administration through inhalation allows both local delivery of the drug to the lungs and systemic therapy. The ethanol injection method used for the liposome production is easily scaled up and is characterized by simplicity and low cost. Vesicles were prepared using different lipid compositions, including hydrogenated soybean phosphatidylcholine and cholesterol (SPC/Chol), egg phosphatidylcholine and cholesterol (EPC/Chol), distearoyl phosphatidylcholine and cholesterol (DSPC/Chol), distearoyl phosphatidylcholine, dimyristoyl phosphatidylethanolamine and cholesterol (DSPC/DMPE/Chol), dipalmitoyl phosphatidylcholine and cholesterol (DPPC/Chol) and dipalmitoyl phosphatidylcholine, dipalmitoyl phosphatidylglycerol and cholesterol (DPPC/DPPG/Chol). The effects of different operational conditions for vesicle production and drug encapsulation were evaluated, aiming at a compromise between final process cost and suitable vesicle characteristics. The best performance concerning drug incorporation was achieved with the DSPC/Chol system, although its production cost was considerably larger than that of the natural lipids formulations. Encapsulation efficiencies up to 63% and final drug to lipid molar ratios up to 0.1 were obtained for SPC/Chol vesicles presenting mean diameters of 132 nm incubated at 60 degrees C with the drug for 60 min at an initial drug-to-lipid molar ratio of 0.16.
dc.description57
dc.description23-30
dc.languageeng
dc.relationThe Journal Of Pharmacy And Pharmacology
dc.relationJ. Pharm. Pharmacol.
dc.rightsfechado
dc.rights
dc.sourcePubMed
dc.subjectAdministration, Inhalation
dc.subjectAntibiotics, Antitubercular
dc.subjectChemistry, Pharmaceutical
dc.subjectCholesterol
dc.subjectDelayed-action Preparations
dc.subjectDrug Compounding
dc.subjectDrug Stability
dc.subjectEthanol
dc.subjectKanamycin
dc.subjectLiposomes
dc.subjectOctanols
dc.subjectParticle Size
dc.subjectPhosphatidylcholines
dc.subjectSolutions
dc.subjectSolvents
dc.subjectTuberculosis
dc.titleKanamycin Incorporation In Lipid Vesicles Prepared By Ethanol Injection Designed For Tuberculosis Treatment.
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución